Revolutionizing Diabetes Treatment: What Every Doctor Must Know!
Revolutionizing Diabetes Treatment: What Every Doctor Must Know!
Before 2022, interest in diabetes medications was mainly limited to patients with the disease and specialists such as endocrinologists and diabetes specialists. That changed when news broke that Ozempic, a relatively new drug in the US, is also helpful in weight loss.
“When you have type 2 diabetes, your risk of cardiovascular events such as a heart attack or stroke increases. Early research on these medications focused on controlling blood sugar and reducing cardiovascular risks,” explains Dr. Rajesh jain assistant professor in the Department of Clinical Sciences and Community Health. “As more data emerges on these new diabetes medications, we are discovering broader health benefits. They are proving helpful for heart and kidney health, which is why nephrologists and cardiologists are also increasingly prescribing them.”
There are 37.3 million people in the U.S. with diabetes—about 11% of the total population. Before the 2000s, treatment options for type 2 diabetes were limited. Most patients started with metformin, and if it was ineffective, they usually had to switch to insulin therapy. Today, several new classes of drugs offer more options. GLP-1 (glucagon-like peptide-1) receptor agonists and, more recently, SGLT-2 (sodium-glucose co-transporter-2) inhibitors have expanded the treatment landscape. These medications work in different ways: SGLT-2 inhibitors prevent the kidneys from reabsorbing glucose, allowing excess sugar to be excreted through urine, while GLP-1 receptor agonists stimulate the body’s insulin production and reduce levels of glucagon, a hormone that raises blood sugar. Of these newer drugs, Ozempic — the brand name for semaglutide and part of the GLP-1 class — has become the best-known, particularly for its once-weekly dosing and weight loss benefits. “Initially, the focus was solely on treating diabetes,” says Dr. Rajesh jain . “But if you look at the trends over the last 10 to 15 years, the rise in obesity has mirrored the growth of diabetes. It’s no surprise that these conditions are now being addressed together.”
According to Dr. Rajesh Jain, this new class of drugs has shown promising results in people with obesity but without diabetes, showing not only weight loss but also metabolic and cardiovascular benefits. However, she cautions that these drugs are not a cure for every disease—they are most effective when combined with healthy lifestyle changes, including diet and exercise.
Like other GLP-1 receptor agonists, Ozempic works by suppressing appetite, improving insulin sensitivity, and slowing down the digestive process. “We advise patients to eat smaller amounts,” Ahmed explains. “If they eat more than they can before their stomachs empty, they may have side effects such as nausea and vomiting.”
While these drugs represent a major advance in treatment, they also highlight the continued importance of maintaining healthy habits for lasting success.
Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments
Type 1 diabetes (T1D) is a chronic autoimmune disease that affects millions of people worldwide. The primary treatment is insulin therapy, typically administered via injection or pump. However, ongoing research is exploring several alternative and adjunctive treatment options, including oral insulin.
This article presents a detailed overview of current and emerging therapies for T1D, with a particular focus on oral insulin. It is organized into sections covering immune-targeted therapies, antigen-based vaccines, cell-directed therapies, cytokine-targeting interventions, and non-immunomodulatory adjunctive therapies.
In the section on non-immunomodulatory therapies, the article examines both the benefits and limitations of drugs such as metformin, amylin analogs, sodium-glucose cotransporter (SGLT) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and verapamil. These treatments can supplement insulin by improving blood sugar control and overcoming insulin resistance, although they also have side effects.
Oral insulin has been highlighted for its potential to improve patient compliance and provide more stable blood sugar regulation. However, its effectiveness is challenged by the enzymatic and physical barriers of the digestive system. To overcome these obstacles, researchers have explored several strategies, including modifying the insulin molecule, using absorption enhancers or nanoparticles, and combining oral insulin with other adjuvant drugs.
Despite promising progress, significant therapeutic challenges remain in T1D. Future research is expected to prioritize the development of targeted immunotherapy, combination treatment approaches, and optimized oral insulin delivery systems. The ultimate goal is to achieve personalized, precise treatment strategies that improve glycemic control and enhance quality of life for people with type 1 diabetes.
Type 1 diabetes (T1D) is a chronic autoimmune disease that affects millions of people worldwide. While genetic and lifestyle factors contribute to its onset, growing evidence suggests that environmental endocrine-disrupting chemicals (EDCs) also play an important role in the development of diabetes, obesity, and beta cell dysfunction [2]. EDCs are natural or synthetic substances that structurally resemble steroid hormones and can bind to estrogen, progesterone, and androgen receptors, potentially leading to metabolic disorders.
Among the most worrisome EDCs are plasticizers such as bisphenol A (BPA) and pesticides such as dichlorodiphenyltrichloroethane (DDT). BPA, through its interaction with the G protein-coupled receptor 30 (GPR30), suppresses the production of adiponectin, a hormone involved in glucose regulation, which contributes to the onset of type 2 diabetes. It also interferes with insulin secretion by downregulating key genes such as SLC2A2 (glucose transporter) and GCK (glucokinase). DDT, which can be absorbed through inhalation or contact with contaminated surfaces, disrupts hormonal pathways, contributing to insulin resistance and impaired glucose tolerance.
Regardless of these environmental factors, the primary mechanism behind T1D is the immune system’s attack on pancreatic β-cells, which are responsible for the production of insulin. Standard treatment involves regular insulin administration via injection or an insulin pump. However, emerging research is exploring alternative therapies – most notably, oral insulin – as a means of improving disease management. Oral insulin has gained attention for its potential to increase patient compliance and reduce reliance on injections. Many individuals with T1D struggle to maintain strict injection schedules, which can lead to poor glycemic control and increased risk of complications. A non-invasive option such as oral insulin may provide a more convenient and tolerable approach, potentially improving compliance. Furthermore, oral insulin may better replicate the body’s natural insulin release, leading to more stable blood sugar levels. Still, significant challenges hinder the effectiveness of oral insulin. The gastrointestinal tract has both physical and enzymatic barriers that destroy insulin before it can enter the bloodstream. Its large molecular size also makes it difficult for the intestinal wall to absorb it.
To overcome these barriers, researchers are developing innovative strategies to enhance oral insulin delivery. These include modifying the insulin molecule for greater stability, using absorption enhancers or nanoparticles, and combining insulin with other agents such as protease inhibitors and permeation enhancers.
While the potential of oral insulin to transform T1D treatment is promising, much work remains. By exploring ongoing efforts to improve delivery methods and overcome existing barriers, this article provides a comprehensive overview of treatment options for type 1 diabetes, with a particular emphasis on the future of oral insulin. Through continued research and innovation, the goal is to improve glycemic control and quality of life for individuals living with this lifelong condition.
Also Read This Article :
The Future of Diabetes Care: AI, Genetics & Smart Medicine!
About Post Author
